More precise molecular testing may open new paths for rare central nervous system tumours
More precise molecular testing may open new paths for rare central nervous system tumours In oncology, rarity is rarely an advantage. Rare tumours tend to come with fewer studies, fewer established treatment pathways, less diagnostic consensus, and l...
Continue reading







